Growth Strategy: Evidence-Based Reimbursement and Commercialization Strategies for Innovators and Investors
03 November 2010
In today’s rigorous health care environment new products must present a high profit and value proposition to potential investors and acquirers. Along with this increased level of scrutiny, payers are reviewing comparative effectiveness data and more carefully examining economic data for reimbursements. In this session panelists will discuss:
- Medicare product coverage strategy
- Proper planning for product pricing
- Preparing comparative effectiveness data
- Working with payer expectations
- Data that should be in place for partnering or acquisition deals
Panelists:
- Judith A. Waltz, Partner, Foley & Lardner LLP
- Anita Chawla, Ph.D., Vice President, Analysis Group
- Antoun Nabhan, Director of Corporate Development, Onyx Pharmaceuticals
Related Insights
07 February 2025
Health Care Law Today
The Colorado AI Act: Implications for Health Care Providers
Artificial intelligence (AI) is increasingly being integrated into health care operations, from administrative functions such as scheduling and billing to clinical decision-making, including diagnosis and treatment recommendations. Although AI offers significant benefits, concerns regarding bias, transparency, and accountability have prompted regulatory responses.
07 February 2025
Trump Tariffs 2.0: FAQs on How Your Contract Comes into Play
Video FAQ: Does your contract protect you? The Trump administration’s tariffs have reshaped global trade—but how do they impact your contracts? From force majeure to price adjustment clauses, understanding these provisions is critical for protecting your business.
05 February 2025
Manufacturing Industry Advisor
Foley Automotive Update
Foley is here to help you through all aspects of rethinking your long-term business strategies, investments, partnerships, and technology. Contact the authors, your Foley relationship partner, or our Automotive Team to discuss and learn more.